Search results

  1. 1.
    0564874 - MBÚ 2023 RIV US eng J - Journal Article
    Wasserbauer, M. - Hlava, S. - Drábek, J. - Šťovíček, J. - Minaříková, P. - Nedbalová, L. - Drasar, T. - Zadorová, Z. - Dolina, J. - Konečný, S. - Kojecky, V. - Koželuhová, J. - Černíková, P. - Pichlerová, D. - Kučerová, B. - Coufal, Štěpán - Keil, R.
    Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring.
    PLoS ONE. Roč. 17, 8 August (2022), č. článku e0271299. ISSN 1932-6203. E-ISSN 1932-6203
    Institutional support: RVO:61388971
    Keywords : Adalimumab * Biosimilar Pharmaceuticals * Colitis * Ulcerative * Crohn Disease * Humans * Inflammatory Bowel Diseases * Prospective Studies * Remission Induction * Treatment Outcome
    OECD category: General and internal medicine
    Impact factor: 3.7, year: 2022
    Method of publishing: Open access
    https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0271299
    Permanent Link: https://hdl.handle.net/11104/0336441
     
     
  2. 2.
    0556729 - ÚI 2023 RIV NO eng J - Journal Article
    Lukáš, M. - Kolář, M. - Reissigová, Jindra - Ďuricová, D. - Machková, N. - Hrubá, V. - Lukáš, M. - Vašátko, M. - Jirsa, J. - Pudilová, K. - Malíčková, K.
    A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn’s disease: an analysis of two propensity score-matched cohorts.
    Scandinavian Journal of Gastroenterology. Roč. 57, č. 7 (2022), s. 814-824. ISSN 0036-5521. E-ISSN 1502-7708
    Institutional support: RVO:67985807
    Keywords : Crohn’s disease * adalimumab * biosimilar
    OECD category: Statistics and probability
    Impact factor: 1.8, year: 2022
    Method of publishing: Open access
    http://dx.doi.org/10.1080/00365521.2022.2041082
    Permanent Link: http://hdl.handle.net/11104/0330887
    FileDownloadSizeCommentaryVersionAccess
    0556729-afin.pdf52 MBOA CC BY 4.0Author´s preprintopen-access
     
     


  This site uses cookies to make them easier to browse. Learn more about how we use cookies.